These findings provide mechanistic evidence that bilirubin or altered bilirubin metabolism (e.g., partial UGT1A1 inhibitors49) may be useful as a therapeutic approach to reduce obesity and improve insulin resistance and glucose tolerance. The gene discussed is UGT1A1; the disease is obesity due to melanocortin 4 receptor deficiency.